Psychedelics and Cannabis
An All-in-One Unique Profit
Opportunity to Act on Now! International mental health medical company adds psilocybin to its US cannabis patent mix.
With a combined market soaring toward $60 billion,
this could be a monster! Greetings Fellow Investor, Widespread legalization, FDA approvals, breakthrough medical discoveries...and this time it's not just cannabis...it's now also psilocybin. The "magic mushroom," previously known for its psychedelic properties, has been discovered to hold highly efficacious therapeutic potential for treatment of mental disorders and brain injuries. Psychedelics Is a Sector Packed With Winners…
and It's Only the Beginning The FDA has fast-tracked psilocybin after clinical trials prove its efficacy treating PTSD, depression and opioid addiction. I have been watching closely as investors have responded to this emerging market trend…and the results have been breathtaking. I believe I have discovered a company at the right entry point for growth-oriented investors. The potential here could be stunning. To learn more about this opportunity, please read my urgent new report on this company that stands to become one of the market's most important suppliers of cannabinoid compounds and psilocybin to global pharmaceutical markets. Psychedelics and Cannabis Markets Combined
Undergoing a Paradigm Shift I've followed these developments ever since the legalization of medical marijuana gained traction in the US. It's already abundantly clear that the cannabis industry was set to go to industrial scale. Now, psilocybin has been added to the mix and the combination of both in one company promises to be disruptive. You could see massive growth in your wealth if you make the right choices now. From the outset, I anticipated I'd find one forward-looking company emerge with a totally new and transformative business model for producing cannabinoids, and now psychedelic compounds, for use in industrial quantities. I believe independent producers that dominated the last decade of growth simply will not be able to meet the stringent and massive supply requirements about to be created by this booming market. I saw this as inevitable, so I began monitoring a number of producing international companies showing potential to grow seamlessly into this burgeoning arena. One has clearly risen to the top — providing a clear ground floor opportunity — and it trades right here in the US. I've just completed a detailed report into its business model and its exceptional investment potential...and I want you to have it with my compliments. Now Could Be the Ideal Time for You to Get in Front of This Everything about this company has been geared to high-quality, low-cost production of these organic compounds, all in scalable quantities and consistent quality that major buyers can depend upon year-after-year. This will be key to the mainstream adoption of cannabinoids and psilocybin for conventional medicine. Big pharma enters this space with no currently known reliable, scalable combined supply channels for cannabinoids, psilocybin, or other compounds now gathering clinical traction. This company has built a vertically integrated, end-to-end supply chain that extends from plant propagation to high purity extraction. Everything necessary is covered within its own operations — even shipping from its cultivation farms to partnered extraction labs. It also manages one of the world's leading horticultural labs where proprietary plants are developed bearing the highest concentrations of recoverable compounds. Provisional patents related to PTSD have already been granted on their formulation and derived associated intellectual property. Few opportunities I've seen in my multi-decade career show such obvious growth potential...and this one is just getting started. It's a ground floor opportunity with incredible upside potential. Click Here For Your FREE Report
to Discover My Top Pick for 2021 One Last Parting Thought:
In my report you'll find a revenue chart that clearly portrays the stunning pace of growth anticipated for this company. Management forecasts 2021 revenue to grow nearly nine-fold over the next two years, propelled by a blistering hot market just now gaining traction. This is unlikely to remain an entry level opportunity for much longer. I urge you to read my free report without delay.
Yours for Prosperity,
MF Williams, Contributor
For Investor News Service MF Williams came to FNN with an already impressive career analyzing small and microcap companies. He became involved in banking and finance working for BNP Paribas North America in New York City in early 2000. He soon found his true passion in small and microcap sector stocks, with their dramatic potential for upside growth. With over 19 years of experience analyzing and researching emerging small cap public companies, his insight and skill set are unmatched. _________________________ SPONSORED ARTICLE: Investing in any securities is highly speculative. Please be sure to always do your own due diligence before making any investment decisions. Read our full disclaimer here. 
| 
No comments:
Post a Comment